Tonix Pharmaceuticals Completes Positive Pre-IND Meeting with FDA for TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) as a Clinical Candidate for Agitation in Alzheimer’s Disease December 12, 2017 • 7:00 AM EST
Tonix Pharmaceuticals to Present at 10th Annual LD Micro Investor Conference November 30, 2017 • 7:00 AM EST
Tonix Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Programs Update November 7, 2017 • 7:00 AM EST
Tonix Pharmaceuticals to Present at 23rd Annual BIO-Europe International Partnering Conference November 1, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Reports Outcomes from U.S. FDA Breakthrough Therapy CMC Guidance Meeting of Tonmya® (Cyclobenzaprine HCI Sublingual Tablets) for PTSD October 17, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals to Present at the Dawson James Securities 3rd Annual Small Cap Growth Conference October 12, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Presented at the 2nd Annual Cohen Veterans Care Summit in Washington, D.C. September 29, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Receives European Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) September 14, 2017 • 4:05 PM EDT
Tonix Pharmaceuticals Elects Margaret Smith Bell to the Board of Directors September 14, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference September 6, 2017 • 7:00 AM EDT